Pharmacy

Amyloid burden spurs white matter degradation in cognitively normal elderly

Aspirin, cilostazol exert similar effects on white matter changes in cerebral small vessel disease

19 hours ago

The progression of white matter changes in cerebral small vessel disease does not seem to be different between aspirin- and cilostazol-treated patients, a study has found.

Statins help preserve liver function in chronic liver disease

Statins not only good for the heart, but also the liver

Pearl Toh, 21 hours ago

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Community pharmacist intervention helps improve medication adherence

Yesterday

A recent collaborative effort has successfully implemented a community pharmacist-led adherence intervention in several independent pharmacies in Buffalo, New York in the US, which has resulted in increased interactions with patients and, in some cases, improved adherence measures, reports a study.

Methylprednisolone improves major kidney outcomes in patients with IgAN

Elaine Soliven, 2 days ago

Treatment with methylprednisolone reduces the risk of kidney composite outcomes, including kidney failure, 40 percent decline in eGFR, or death due to kidney disease, in patients with IgA nephropathy (IgAN), according to the TESTING* study presented at ASN Kidney Week 2021.

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

Roshini Claire Anthony, 2 days ago

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]

Rapid antigen test: Don’t let perfect be the enemy of good

Pearl Toh, 23 Oct 2021

While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.

ID NOW rapid molecular assay an effective COVID-19 test for kids

Rapid COVID-19 testing: Is it as good in kids?

Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Statins not only good for the heart, but also the liver

Pearl Toh, 27 Nov 2021

Methylprednisolone improves major kidney outcomes in patients with IgAN

Elaine Soliven, 26 Nov 2021

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

Roshini Claire Anthony, 25 Nov 2021

Lumasiran reduces plasma oxalate in advanced PH1

Elvira Manzano, 25 Nov 2021

Treatment with the RNAi therapeutic lumasiran led to a significant reduction in plasma oxalate and pre-dialysis oxalate levels in patients with advanced primary hyperoxaluria type 1 (PH1), according to the 6-month primary analysis of phase III ILLUMINATE-C trial presented at ASN Kidney Week 2021.

Oral daprodustat on par with ESA for anaemia in CKD

Oral daprodustat: A ‘transformative’ care for anaemia in CKD?

Pearl Toh, 24 Nov 2021

The oral HIF-PHI* daprodustat was noninferior to standard treatment with erythropoiesis-stimulating agents (ESAs) for increasing haemoglobin levels to within target range, without increasing cardiovascular (CV) risk in patients with anaemia due to chronic kidney disease (CKD), regardless of whether they were dialysis dependent or not, according to the phase III ASCEND-D/-ND trials presented at ASN 2021.

Dupilumab benefits in EoE sustained through 52 weeks

Pearl Toh, 23 Nov 2021

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

Audrey Abella, 22 Nov 2021

Data presented at AHA 2021 demonstrated the efficacy and safety of bempedoic acid for improving lipid and glycaemic parameters and hsCRP irrespective of metabolic status.